A Toronto Stock Exchange logo is seen in Toronto in this file photo.Mark Blinch
Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:
The TSX Composite Earnings Scorecard is the most comprehensive and up-to-the-minute compilation of aggregated earnings growth and market intelligence covering the companies included in the TSX Composite Index. This report combines Thomson Reuters' unrivaled historical earnings database, in-depth coverage of sell-side analysts' bottom-up corporate earnings estimates, and the analytic capabilities of Thomson Reuters Proprietary Research Group and desktop solutions.
EARNINGS HIGHLIGHTS
Q2 2017 Y/Y Blended Earnings Growth Estimates
- TSX Composite (.GSPTSE) = 20.8 per cent
- Ex-Energy = 13.7 per cent
- Valeant Pharmaceuticals International Inc. = -29.0 per cent
- Healthcare Ex- VRX = -1.2 per cent
- TSX Composite Ex-VRX = 21.8 per cent
Q2 2017 Performance vs. Earnings Expectations
Ninety-eight per cent of the TSX Composite companies have reported Q3 2017 EPS. Of the 239 companies in the index that have reported earnings to date for Q2 2017:
- 54.0 per cent reported above analyst expectations
- 34.7 per cent reported below analyst expectations
Q3 2017 Y/Y Blended Earnings Growth Estimates
- TSX Composite = 14.7 per cent
- Ex-Energy = 7.7 per cent
- Valeant Pharmaceuticals = -35.5 per cent
- Healthcare Ex- VRX = -39.0 per cent
- TSX Composite Ex-VRX = 15.7 per cent
REVENUE HIGHLIGHTS
Q2 2017 Y/Y Blended Revenue Growth Estimates
- TSX Composite = 7.3 per cent
- Ex-Energy = 3.4 per cent
- Valeant Pharma. (VRX.TO) = -10.9 per cent
- Healthcare Ex-Valeant Pharma. = 7.9 per cent
- TSX Composite Ex-Valeant Pharma. = 7.5 per cent
Q2 2017 Performance vs. Revenue Expectations
Of the TSX Composite companies that have reported revenue to date for Q3 2017:
- 60.2 per cent reported above analyst expectations
- 39.4 per cent reported below analyst expectations
Q3 2017 Y/Y Blended Revenue Growth Estimates
- TSX Composite (.GSPTSE) = 8.1 per cent
- Ex-Energy = 6.6 per cent
- Valeant Pharmaceuticals = -14.0 per cent
- Healthcare Ex-Valeant Pharma = 5.9 per cent
- TSX Composite Ex-Valeant Pharma = 8.4 per cent
Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.
Globe app users click here for the full report
Read other research reports here.